procalcitonin
biomark
differenti
bacteri
infect
engraft
syndrom
follow
autolog
hematopoiet
stem
cell
transplant
multipl
myeloma
editor
procalcitonin
pct
hormokin
approv
food
drug
agenc
biomark
sepsi
found
use
prognost
biomark
febril
neutropen
patient
document
infect
infecti
complic
major
caus
morbid
mortal
febril
neutropen
patient
asct
fever
therefor
frequent
treat
antibiot
howev
unnecessari
use
broadspectrum
antibiot
treatment
harbor
risk
evolut
drug
resist
bacteria
clostridium
difficil
infect
previous
report
high
resourc
util
associ
lateonset
fever
engraft
syndrom
es
follow
autolog
stem
cell
transplant
asct
median
hospit
lengthofstay
patient
develop
es
day
longer
without
es
patient
also
incur
averag
addit
cost
patient
multipl
myeloma
mm
risk
develop
es
follow
asct
patient
develop
complic
high
incid
attribut
prior
use
bortezomib
lenalidomid
sixtysix
percent
men
autolog
peripher
blood
stem
cell
mobil
use
gcsf
ae
plerixafor
pct
cutoff
ngml
might
adjunct
biomark
identifi
patient
suffer
noninfecti
fever
associ
es
follow
asct
pct
guid
algorithm
may
limit
durat
antibiot
reduc
advers
event
prevent
emerg
antimicrobi
resist
larg
random
control
trial
compar
pct
guid
antimicrobi
therapi
vs
standard
care
limit
unnecessari
exposur
antimicrobi
immunocompromis
asct
recipi
warrant
noth
report
definit
clinic
evid
causal
associ
describ
drug
food
supplement
drug
food
supplement
previous
describ
definit
evid
nine
articl
report
evalu
group
data
one
report
quinin
treatment
describ
definit
evid
causal
associ
quinin
previous
report
definit
evid
support
inform
tabl
summar
data
evalu
report
patient
articl
report
evalu
group
data
new
data
systemat
literatur
review
togeth
new
data
bloodcent
wisconsin
merg
previous
report
data
updat
web
site
